Belantamab mafodotin associated corneal microcyst-like epithelial changes
Purpose: To report a case of bilateral corneal microcyst-like epithelial changes associated with belantamab mafodotin (belamaf) therapy. Observations: A 70-year-old man with refractory multiple myeloma was placed on belamaf, a recently FDA-approved treatment for relapsed or refractory multiple myelo...
Main Authors: | Chuang, K. (Author), Liu, S. (Author), Pineda, R. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier Inc.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
by: Asim V. Farooq, et al.
Published: (2020-07-01) -
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021-08-01) -
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
by: Ahsan Wahab, et al.
Published: (2021-05-01) -
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
by: Grace Lassiter, et al.
Published: (2021-01-01) -
Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape
by: Rebecca Gonzalez, et al.
Published: (2021-07-01)